Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 12 entries
Sorted by: Best Match Show Resources per page
GATA3 is not a diagnostic biomarker of central nervous system paragangliomas.

Human pathology

Tauziède-Espariat A, Mehdi L, Gareton A, Laquerrière A, Adle-Biassette H, Polivka M, Cazals-Hatem D, Varlet P, Lechapt-Zalcman E.
PMID: 33524437
Hum Pathol. 2021 Dec;118:86-87. doi: 10.1016/j.humpath.2021.01.004. Epub 2021 Jan 29.

No abstract available.

Cite
Tauziède-Espariat A, Mehdi L, Gareton A, et al. GATA3 is not a diagnostic biomarker of central nervous system paragangliomas. Hum Pathol. 2021;118:86-87doi: 10.1016/j.humpath.2021.01.004.
Tauziède-Espariat, A., Mehdi, L., Gareton, A., Laquerrière, A., Adle-Biassette, H., Polivka, M., Cazals-Hatem, D., Varlet, P., & Lechapt-Zalcman, E. (2021). GATA3 is not a diagnostic biomarker of central nervous system paragangliomas. Human pathology, 11886-87. https://doi.org/10.1016/j.humpath.2021.01.004
Tauziède-Espariat, Arnault, et al. "GATA3 is not a diagnostic biomarker of central nervous system paragangliomas." Human pathology vol. 118 (2021): 86-87. doi: https://doi.org/10.1016/j.humpath.2021.01.004
Tauziède-Espariat A, Mehdi L, Gareton A, Laquerrière A, Adle-Biassette H, Polivka M, Cazals-Hatem D, Varlet P, Lechapt-Zalcman E. GATA3 is not a diagnostic biomarker of central nervous system paragangliomas. Hum Pathol. 2021 Dec;118:86-87. doi: 10.1016/j.humpath.2021.01.004. Epub 2021 Jan 29. PMID: 33524437.
Copy Download .nbib Format: NLM
GATA3 is not a diagnostic biomarker of central nervous system paragangliomas.

Human pathology

Tauziède-Espariat A, Mehdi L, Gareton A, Laquerrière A, Adle-Biassette H, Polivka M, Cazals-Hatem D, Varlet P, Lechapt-Zalcman E.
PMID: 33524437
Hum Pathol. 2021 Dec;118:86-87. doi: 10.1016/j.humpath.2021.01.004. Epub 2021 Jan 29.

No abstract available.

Cite
Tauziède-Espariat A, Mehdi L, Gareton A, et al. GATA3 is not a diagnostic biomarker of central nervous system paragangliomas. Hum Pathol. 2021;118:86-87doi: 10.1016/j.humpath.2021.01.004.
Tauziède-Espariat, A., Mehdi, L., Gareton, A., Laquerrière, A., Adle-Biassette, H., Polivka, M., Cazals-Hatem, D., Varlet, P., & Lechapt-Zalcman, E. (2021). GATA3 is not a diagnostic biomarker of central nervous system paragangliomas. Human pathology, 11886-87. https://doi.org/10.1016/j.humpath.2021.01.004
Tauziède-Espariat, Arnault, et al. "GATA3 is not a diagnostic biomarker of central nervous system paragangliomas." Human pathology vol. 118 (2021): 86-87. doi: https://doi.org/10.1016/j.humpath.2021.01.004
Tauziède-Espariat A, Mehdi L, Gareton A, Laquerrière A, Adle-Biassette H, Polivka M, Cazals-Hatem D, Varlet P, Lechapt-Zalcman E. GATA3 is not a diagnostic biomarker of central nervous system paragangliomas. Hum Pathol. 2021 Dec;118:86-87. doi: 10.1016/j.humpath.2021.01.004. Epub 2021 Jan 29. PMID: 33524437.
Copy Download .nbib Format: NLM
Aetiological factors of Budd-Chiari syndrome in Algeria.

World journal of hepatology

Afredj N, Guessab N, Nani A, Faraoun SA, Ouled Cheikh I, Kerbouche R, Hannoun D, Amir ZC, Ait Kaci H, Bentabak K, Plessier A, Valla DC, Cazals-Hatem V, Denninger MH, Boucekkine T, Debzi N.
PMID: 25937867
World J Hepatol. 2015 Apr 28;7(6):903-9. doi: 10.4254/wjh.v7.i6.903.

AIM: To study the clinical presentation of Budd-Chiari syndrome (BCS) and identify the aetiologies of this disease in Algeria.METHODS: Patients with BCS, hospitalised in our unit from January 2004 until June 2010 were included and the aetiological factors were...

Cite
Afredj N, Guessab N, Nani A, et al. Aetiological factors of Budd-Chiari syndrome in Algeria. World J Hepatol. 2015;7(6):903-9doi: 10.4254/wjh.v7.i6.903.
Afredj, N., Guessab, N., Nani, A., Faraoun, S. A., Ouled Cheikh, I., Kerbouche, R., Hannoun, D., Amir, Z. C., Ait Kaci, H., Bentabak, K., Plessier, A., Valla, D. C., Cazals-Hatem, V., Denninger, M. H., Boucekkine, T., & Debzi, N. (2015). Aetiological factors of Budd-Chiari syndrome in Algeria. World journal of hepatology, 7(6), 903-9. https://doi.org/10.4254/wjh.v7.i6.903
Afredj, Nawel, et al. "Aetiological factors of Budd-Chiari syndrome in Algeria." World journal of hepatology vol. 7,6 (2015): 903-9. doi: https://doi.org/10.4254/wjh.v7.i6.903
Afredj N, Guessab N, Nani A, Faraoun SA, Ouled Cheikh I, Kerbouche R, Hannoun D, Amir ZC, Ait Kaci H, Bentabak K, Plessier A, Valla DC, Cazals-Hatem V, Denninger MH, Boucekkine T, Debzi N. Aetiological factors of Budd-Chiari syndrome in Algeria. World J Hepatol. 2015 Apr 28;7(6):903-9. doi: 10.4254/wjh.v7.i6.903. PMID: 25937867; PMCID: PMC4411532.
Copy Download .nbib Format: NLM
Middle ear adenomatous neuroendocrine tumours: Single institution experience with five cases.

Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery

Alciato L, Lahlou G, Tankéré F, Cazals-Hatem D, Bozorg-Grayeli A, Sterkers O, Bernardeschi D.
PMID: 33934510
Clin Otolaryngol. 2021 Sep;46(5):1136-1141. doi: 10.1111/coa.13791. Epub 2021 May 31.

No abstract available.

Cite
Alciato L, Lahlou G, Tankéré F, et al. Middle ear adenomatous neuroendocrine tumours: Single institution experience with five cases. Clin Otolaryngol. 2021;46(5):1136-1141doi: 10.1111/coa.13791.
Alciato, L., Lahlou, G., Tankéré, F., Cazals-Hatem, D., Bozorg-Grayeli, A., Sterkers, O., & Bernardeschi, D. (2021). Middle ear adenomatous neuroendocrine tumours: Single institution experience with five cases. Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery, 46(5), 1136-1141. https://doi.org/10.1111/coa.13791
Alciato, Lauranne, et al. "Middle ear adenomatous neuroendocrine tumours: Single institution experience with five cases." Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery vol. 46,5 (2021): 1136-1141. doi: https://doi.org/10.1111/coa.13791
Alciato L, Lahlou G, Tankéré F, Cazals-Hatem D, Bozorg-Grayeli A, Sterkers O, Bernardeschi D. Middle ear adenomatous neuroendocrine tumours: Single institution experience with five cases. Clin Otolaryngol. 2021 Sep;46(5):1136-1141. doi: 10.1111/coa.13791. Epub 2021 May 31. PMID: 33934510.
Copy Download .nbib Format: NLM
Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome.

JHEP reports : innovation in hepatology

Van Wettere M, Paulatto L, Raynaud L, Bruno O, Payancé A, Plessier A, Rautou PE, Paradis V, Cazals-Hatem D, Valla D, Vilgrain V, Ronot M.
PMID: 32435753
JHEP Rep. 2020 Mar 09;2(3):100097. doi: 10.1016/j.jhepr.2020.100097. eCollection 2020 Jun.

BACKGROUND & AIMS: Hepatobiliary phase (HBP) images can discriminate between benign and malignant liver lesions, but it is unclear if this approach can be used in patients with Budd-Chiari syndrome (BCS). Thus, we aimed to assess the diagnostic utility...

Cite
Van Wettere M, Paulatto L, Raynaud L, et al. Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome. JHEP Rep. 2020;2(3):100097doi: 10.1016/j.jhepr.2020.100097.
Van Wettere, M., Paulatto, L., Raynaud, L., Bruno, O., Payancé, A., Plessier, A., Rautou, P. E., Paradis, V., Cazals-Hatem, D., Valla, D., Vilgrain, V., & Ronot, M. (2020). Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome. JHEP reports : innovation in hepatology, 2(3), 100097. https://doi.org/10.1016/j.jhepr.2020.100097
Van Wettere, Morgane, et al. "Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome." JHEP reports : innovation in hepatology vol. 2,3 (2020): 100097. doi: https://doi.org/10.1016/j.jhepr.2020.100097
Van Wettere M, Paulatto L, Raynaud L, Bruno O, Payancé A, Plessier A, Rautou PE, Paradis V, Cazals-Hatem D, Valla D, Vilgrain V, Ronot M. Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome. JHEP Rep. 2020 Mar 09;2(3):100097. doi: 10.1016/j.jhepr.2020.100097. eCollection 2020 Jun. PMID: 32435753; PMCID: PMC7232085.
Copy Download .nbib Format: NLM
Letter to the Editor: Serum Aminotransferase Activity Beyond 100 Times the Upper Limit of Normal Value Does Not Suggest Acute Fatty Liver of Pregnancy Alone.

Hepatology (Baltimore, Md.)

Bernuau J, Cazals-Hatem D, Vigrain V, Durand F.
PMID: 34268791
Hepatology. 2021 Nov;74(5):2922. doi: 10.1002/hep.32039. Epub 2021 Aug 15.

No abstract available.

Cite
Bernuau J, Cazals-Hatem D, Vigrain V, et al. Letter to the Editor: Serum Aminotransferase Activity Beyond 100 Times the Upper Limit of Normal Value Does Not Suggest Acute Fatty Liver of Pregnancy Alone. Hepatology. 2021;74(5):2922doi: 10.1002/hep.32039.
Bernuau, J., Cazals-Hatem, D., Vigrain, V., & Durand, F. (2021). Letter to the Editor: Serum Aminotransferase Activity Beyond 100 Times the Upper Limit of Normal Value Does Not Suggest Acute Fatty Liver of Pregnancy Alone. Hepatology (Baltimore, Md.), 74(5), 2922. https://doi.org/10.1002/hep.32039
Bernuau, Jacques, et al. "Letter to the Editor: Serum Aminotransferase Activity Beyond 100 Times the Upper Limit of Normal Value Does Not Suggest Acute Fatty Liver of Pregnancy Alone." Hepatology (Baltimore, Md.) vol. 74,5 (2021): 2922. doi: https://doi.org/10.1002/hep.32039
Bernuau J, Cazals-Hatem D, Vigrain V, Durand F. Letter to the Editor: Serum Aminotransferase Activity Beyond 100 Times the Upper Limit of Normal Value Does Not Suggest Acute Fatty Liver of Pregnancy Alone. Hepatology. 2021 Nov;74(5):2922. doi: 10.1002/hep.32039. Epub 2021 Aug 15. PMID: 34268791.
Copy Download .nbib Format: NLM
A novel SMARCA2-CREM fusion: expanding the molecular spectrum of intracranial mesenchymal tumors beyond the FET genes.

Acta neuropathologica communications

Tauziède-Espariat A, Pierron G, Guillemot D, Sievers P, Cazals-Hatem D, Faillot T, Roux A, Benzakoun J, Bockel S, Weinbreck N, Hasty L, Lechapt E, Chrétien F, Varlet P.
PMID: 34715942
Acta Neuropathol Commun. 2021 Oct 29;9(1):174. doi: 10.1186/s40478-021-01278-4.

A novel histomolecular tumor of the central nervous system, the "intracranial mesenchymal tumor (IMT), FET-CREB fusion-positive" has recently been identified in the literature and will be added to the 2021 World Health Organization Classification of Tumors of the Central...

Cite
Tauziède-Espariat A, Pierron G, Guillemot D, et al. A novel SMARCA2-CREM fusion: expanding the molecular spectrum of intracranial mesenchymal tumors beyond the FET genes. Acta Neuropathol Commun. 2021;9(1):174doi: 10.1186/s40478-021-01278-4.
Tauziède-Espariat, A., Pierron, G., Guillemot, D., Sievers, P., Cazals-Hatem, D., Faillot, T., Roux, A., Benzakoun, J., Bockel, S., Weinbreck, N., Hasty, L., Lechapt, E., Chrétien, F., & Varlet, P. (2021). A novel SMARCA2-CREM fusion: expanding the molecular spectrum of intracranial mesenchymal tumors beyond the FET genes. Acta neuropathologica communications, 9(1), 174. https://doi.org/10.1186/s40478-021-01278-4
Tauziède-Espariat, Arnault, et al. "A novel SMARCA2-CREM fusion: expanding the molecular spectrum of intracranial mesenchymal tumors beyond the FET genes." Acta neuropathologica communications vol. 9,1 (2021): 174. doi: https://doi.org/10.1186/s40478-021-01278-4
Tauziède-Espariat A, Pierron G, Guillemot D, Sievers P, Cazals-Hatem D, Faillot T, Roux A, Benzakoun J, Bockel S, Weinbreck N, Hasty L, Lechapt E, Chrétien F, Varlet P. A novel SMARCA2-CREM fusion: expanding the molecular spectrum of intracranial mesenchymal tumors beyond the FET genes. Acta Neuropathol Commun. 2021 Oct 29;9(1):174. doi: 10.1186/s40478-021-01278-4. PMID: 34715942; PMCID: PMC8555238.
Copy Download .nbib Format: NLM
CARMN-NOTCH2 fusion transcript drives high NOTCH2 expression in glomus tumors of the upper digestive tract.

Genes, chromosomes & cancer

Girard N, Marin C, Hélias-Rodzewicz Z, Villa C, Julié C, de Lajarte-Thirouard AS, de Beauce SM, Lagorce-Pages C, Renaud F, Cazals-Hatem D, Guedj N, Cros J, Raffin-Sanson ML, Selves J, Terris B, Fléjou JF, Garchon HJ, Coindre JM, Emile JF.
PMID: 34245196
Genes Chromosomes Cancer. 2021 Nov;60(11):723-732. doi: 10.1002/gcc.22981. Epub 2021 Jul 21.

Glomus tumors (GTs) are perivascular tumors mostly occurring in the distal extremities. Rare cases arise in the digestive tract and may be misdiagnosed with neuroendocrine or gastrointestinal stromal tumors. We aimed to specify the features of GT of the...

Cite
Girard N, Marin C, Hélias-Rodzewicz Z, et al. CARMN-NOTCH2 fusion transcript drives high NOTCH2 expression in glomus tumors of the upper digestive tract. Genes Chromosomes Cancer. 2021;60(11):723-732doi: 10.1002/gcc.22981.
Girard, N., Marin, C., Hélias-Rodzewicz, Z., Villa, C., Julié, C., de Lajarte-Thirouard, A. S., de Beauce, S. M., Lagorce-Pages, C., Renaud, F., Cazals-Hatem, D., Guedj, N., Cros, J., Raffin-Sanson, M. L., Selves, J., Terris, B., Fléjou, J. F., Garchon, H. J., Coindre, J. M., & Emile, J. F. (2021). CARMN-NOTCH2 fusion transcript drives high NOTCH2 expression in glomus tumors of the upper digestive tract. Genes, chromosomes & cancer, 60(11), 723-732. https://doi.org/10.1002/gcc.22981
Girard, Nicolas, et al. "CARMN-NOTCH2 fusion transcript drives high NOTCH2 expression in glomus tumors of the upper digestive tract." Genes, chromosomes & cancer vol. 60,11 (2021): 723-732. doi: https://doi.org/10.1002/gcc.22981
Girard N, Marin C, Hélias-Rodzewicz Z, Villa C, Julié C, de Lajarte-Thirouard AS, de Beauce SM, Lagorce-Pages C, Renaud F, Cazals-Hatem D, Guedj N, Cros J, Raffin-Sanson ML, Selves J, Terris B, Fléjou JF, Garchon HJ, Coindre JM, Emile JF. CARMN-NOTCH2 fusion transcript drives high NOTCH2 expression in glomus tumors of the upper digestive tract. Genes Chromosomes Cancer. 2021 Nov;60(11):723-732. doi: 10.1002/gcc.22981. Epub 2021 Jul 21. PMID: 34245196.
Copy Download .nbib Format: NLM
Smooth muscular layer: A new helpful criterion to reclassify tumor deposits into metastatic lymph nodes in patients with colo-rectal adenocarcinoma.

Annals of diagnostic pathology

Wacquet J, Poté N, Cazals-Hatem D, Maggiori L, Panis Y, Guedj N.
PMID: 34265572
Ann Diagn Pathol. 2021 Oct;54:151771. doi: 10.1016/j.anndiagpath.2021.151771. Epub 2021 Jun 16.

CONTEXT: The origin of tumor deposit in colorectal cancer is still unknown, and currently there is no single morphological feature to distinguish a metastatic lymph node from a tumor deposit. Histologically, the normal lymph node capsule and trabeculae contain...

Cite
Wacquet J, Poté N, Cazals-Hatem D, et al. Smooth muscular layer: A new helpful criterion to reclassify tumor deposits into metastatic lymph nodes in patients with colo-rectal adenocarcinoma. Ann Diagn Pathol. 2021;54:151771doi: 10.1016/j.anndiagpath.2021.151771.
Wacquet, J., Poté, N., Cazals-Hatem, D., Maggiori, L., Panis, Y., & Guedj, N. (2021). Smooth muscular layer: A new helpful criterion to reclassify tumor deposits into metastatic lymph nodes in patients with colo-rectal adenocarcinoma. Annals of diagnostic pathology, 54151771. https://doi.org/10.1016/j.anndiagpath.2021.151771
Wacquet, Justine, et al. "Smooth muscular layer: A new helpful criterion to reclassify tumor deposits into metastatic lymph nodes in patients with colo-rectal adenocarcinoma." Annals of diagnostic pathology vol. 54 (2021): 151771. doi: https://doi.org/10.1016/j.anndiagpath.2021.151771
Wacquet J, Poté N, Cazals-Hatem D, Maggiori L, Panis Y, Guedj N. Smooth muscular layer: A new helpful criterion to reclassify tumor deposits into metastatic lymph nodes in patients with colo-rectal adenocarcinoma. Ann Diagn Pathol. 2021 Oct;54:151771. doi: 10.1016/j.anndiagpath.2021.151771. Epub 2021 Jun 16. PMID: 34265572.
Copy Download .nbib Format: NLM
Colonic involvement in acute mesenteric ischemia: prevalence, risk factors, and outcomes.

European radiology

Ksouri A, Copin P, Bonvalet F, Bozi L, Cazals-Hatem D, Garzelli L, Panis Y, Weiss E, Castier Y, Bouhnik Y, Corcos O, Vilgrain V, Ronot M, Nuzzo A.
PMID: 34657969
Eur Radiol. 2021 Oct 18; doi: 10.1007/s00330-021-08318-6. Epub 2021 Oct 18.

OBJECTIVES: This study aimed to investigate the prevalence, risk factors, and outcomes of colonic involvement in patients with acute mesenteric ischemia (AMI).METHODS: CT scans from a prospective cohort of 114 AMI patients treated in an intestinal stroke center between...

Cite
Ksouri A, Copin P, Bonvalet F, et al. Colonic involvement in acute mesenteric ischemia: prevalence, risk factors, and outcomes. Eur Radiol. 2021;doi: 10.1007/s00330-021-08318-6.
Ksouri, A., Copin, P., Bonvalet, F., Bozi, L., Cazals-Hatem, D., Garzelli, L., Panis, Y., Weiss, E., Castier, Y., Bouhnik, Y., Corcos, O., Vilgrain, V., Ronot, M., & Nuzzo, A. (2021). Colonic involvement in acute mesenteric ischemia: prevalence, risk factors, and outcomes. European radiology, . https://doi.org/10.1007/s00330-021-08318-6
Ksouri, Aida, et al. "Colonic involvement in acute mesenteric ischemia: prevalence, risk factors, and outcomes." European radiology vol. (2021). doi: https://doi.org/10.1007/s00330-021-08318-6
Ksouri A, Copin P, Bonvalet F, Bozi L, Cazals-Hatem D, Garzelli L, Panis Y, Weiss E, Castier Y, Bouhnik Y, Corcos O, Vilgrain V, Ronot M, Nuzzo A. Colonic involvement in acute mesenteric ischemia: prevalence, risk factors, and outcomes. Eur Radiol. 2021 Oct 18; doi: 10.1007/s00330-021-08318-6. Epub 2021 Oct 18. PMID: 34657969.
Copy Download .nbib Format: NLM
Letter to the Editor: Serum Aminotransferase Activity Beyond 100 Times the Upper Limit of Normal Value Does Not Suggest Acute Fatty Liver of Pregnancy Alone.

Hepatology (Baltimore, Md.)

Bernuau J, Cazals-Hatem D, Vigrain V, Durand F.
PMID: 34268791
Hepatology. 2021 Nov;74(5):2922. doi: 10.1002/hep.32039. Epub 2021 Aug 15.

No abstract available.

Cite
Bernuau J, Cazals-Hatem D, Vigrain V, et al. Letter to the Editor: Serum Aminotransferase Activity Beyond 100 Times the Upper Limit of Normal Value Does Not Suggest Acute Fatty Liver of Pregnancy Alone. Hepatology. 2021;74(5):2922doi: 10.1002/hep.32039.
Bernuau, J., Cazals-Hatem, D., Vigrain, V., & Durand, F. (2021). Letter to the Editor: Serum Aminotransferase Activity Beyond 100 Times the Upper Limit of Normal Value Does Not Suggest Acute Fatty Liver of Pregnancy Alone. Hepatology (Baltimore, Md.), 74(5), 2922. https://doi.org/10.1002/hep.32039
Bernuau, Jacques, et al. "Letter to the Editor: Serum Aminotransferase Activity Beyond 100 Times the Upper Limit of Normal Value Does Not Suggest Acute Fatty Liver of Pregnancy Alone." Hepatology (Baltimore, Md.) vol. 74,5 (2021): 2922. doi: https://doi.org/10.1002/hep.32039
Bernuau J, Cazals-Hatem D, Vigrain V, Durand F. Letter to the Editor: Serum Aminotransferase Activity Beyond 100 Times the Upper Limit of Normal Value Does Not Suggest Acute Fatty Liver of Pregnancy Alone. Hepatology. 2021 Nov;74(5):2922. doi: 10.1002/hep.32039. Epub 2021 Aug 15. PMID: 34268791.
Copy Download .nbib Format: NLM
Computational Learning of microRNA-Based Prediction of Pouchitis Outcome After Restorative Proctocolectomy in Patients With Ulcerative Colitis.

Inflammatory bowel diseases

Morilla I, Uzzan M, Cazals-Hatem D, Colnot N, Panis Y, Nancey S, Boschetti G, Amiot A, Tréton X, Ogier-Denis E, Daniel F.
PMID: 33609036
Inflamm Bowel Dis. 2021 Oct 18;27(10):1653-1660. doi: 10.1093/ibd/izab030.

BACKGROUND: Ileal pouch-anal anastomosis (IPAA) is the standard of care after total proctocolectomy for ulcerative colitis (UC). However, inflammation often develops in the pouch, leading to acute or recurrent/chronic pouchitis (R/CP). MicroRNAs (miRNA) are used as accurate diagnostic and...

Cite
Morilla I, Uzzan M, Cazals-Hatem D, et al. Computational Learning of microRNA-Based Prediction of Pouchitis Outcome After Restorative Proctocolectomy in Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2021;27(10):1653-1660doi: 10.1093/ibd/izab030.
Morilla, I., Uzzan, M., Cazals-Hatem, D., Colnot, N., Panis, Y., Nancey, S., Boschetti, G., Amiot, A., Tréton, X., Ogier-Denis, E., & Daniel, F. (2021). Computational Learning of microRNA-Based Prediction of Pouchitis Outcome After Restorative Proctocolectomy in Patients With Ulcerative Colitis. Inflammatory bowel diseases, 27(10), 1653-1660. https://doi.org/10.1093/ibd/izab030
Morilla, Ian, et al. "Computational Learning of microRNA-Based Prediction of Pouchitis Outcome After Restorative Proctocolectomy in Patients With Ulcerative Colitis." Inflammatory bowel diseases vol. 27,10 (2021): 1653-1660. doi: https://doi.org/10.1093/ibd/izab030
Morilla I, Uzzan M, Cazals-Hatem D, Colnot N, Panis Y, Nancey S, Boschetti G, Amiot A, Tréton X, Ogier-Denis E, Daniel F. Computational Learning of microRNA-Based Prediction of Pouchitis Outcome After Restorative Proctocolectomy in Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2021 Oct 18;27(10):1653-1660. doi: 10.1093/ibd/izab030. PMID: 33609036.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 12 entries